GLP-1 receptor agonists reduce the incidence of obesity-associated cancers.
- Current status
- Preliminary signalEvidence unclear · Cancer
- Why
- A large EHR cohort in type 2 diabetes found lower incidence of 10 of 13 obesity-associated cancers versus insulin, with weaker or null results versus metformin. Observational, susceptible to confounding by indication and surveillance differences; no randomized cancer-outcome data.
- What would change it
- Prespecified cancer outcomes from large RCTs or an active-comparator cohort with negative-control outcomes.
- Linked studies
- 1 · 1 supports
- Last updated
- Sep 13, 2026
The status is the collection's own judgment on its assessment scale, not a GRADE certainty rating and not medical advice.
01The evidence
The evidence, sorted by what it shows
Supports (1)
- Glucagon-Like Peptide 1 Receptor Agonists and 13 Obesity-Associated Cancers in Patients With Type 2 DiabetesRetrospective cohort · 2024 · Study tier 4 · Different population · Benefit
1.65 million T2D patients; HRs 0.35-0.76 vs insulin for 10 cancers; comparisons vs metformin mostly null.
02History
How this assessment has changed
- Preliminary signalSep 13, 2026 · Evidence unclear
initial curated status